Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;79(3-4):171-180.
doi: 10.1024/0040-5930/a001345.

[Curative Treatment of Esophageal Carcinoma - Disease, Diagnostics, Therapy in 2022]

[Article in German]
Affiliations

[Curative Treatment of Esophageal Carcinoma - Disease, Diagnostics, Therapy in 2022]

[Article in German]
Ulrich Klaus Fetzner et al. Ther Umsch. 2022 Apr.

Abstract

Curative Treatment of Esophageal Carcinoma - Disease, Diagnostics, Therapy in 2022 Abstract. Surgical resection remains the gold standard for non-metastatic carcinoma of the lower and middle third of the esophagus. Locally advanced tumors (T3) are pretreated neoadjuvantly (radiochemotherapy) or perioperatively (chemotherapy). A differentiated primary staging and an interdisciplinary case presentation are of essential importance today. The individual risk assessment, the pre-habilitation and the individualized treatment play a major role. Clinically, the further advancement of access minimization - through laparoscopic/thoracoscopic and robot-assisted procedures and the associated reduction of access trauma - as well as the treatment of this entity in high volume centers are clearly in the foreground. For cervical carcinomas definitive radiotherapy is often the better alternative, both for tumor biological reasons and for reasons of the increase in complications during surgery.

Zusammenfassung. Beim nicht metastasiertem Karzinom des unteren und mittleren Drittels der Speiseröhre bleibt die chirurgische Resektion der Goldstandard. Lokal fortgeschrittene Tumore (T3) werden hierbei neoadjuvant (Radiochemotherapie) oder perioperativ (Chemotherapie) vorbehandelt. Einem differenzierten Primärstaging und einer interdisziplinären Fallvorstellung kommen heute essenzielle Bedeutung zu. Dabei spielt die individuelle Risikobewertung, die Prähabilitation und die individualisierte Behandlung eine grosse Rolle. Die Zugangsminimierung – durch laparoskopische/thorakoskopische und roboterassistierte Verfahren – und die damit verbundene Reduktion des Zugangstraumas, sowie die Versorgung dieser Entität in geeigneten Zentren sind die aktuell dominierenden klinisch-chirurgischen Themen. Für zervikale Karzinome stellt die definitive Radiotherapie sowohl aus tumorbiologischen Gründen als auch aus Gründen der Komplikationsanstieges bei Operationen oft die bessere Alternative dar.

PubMed Disclaimer

MeSH terms

LinkOut - more resources